Q-omics provides the consensus-scored RTL3 profile across patient tissues and cancer cell-line models. RTL3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RTL3 is differentially expressed in 12, with the highest sampling consensus in UCEC. Additionally, RTL3 RNA expression shows 13,959 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, UCEC, and GBM as cancer lineages where RTL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTL3 survival associations across molecular data types. RTL3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTL3 RNA expression–survival associations across cancer types. High RTL3 expression shows unfavorable associations in ACC, KICH, MESO, KIRP, UVM and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RTL3 RNA expression.
This table summarizes RTL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RTL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTL3 shows lower tumor expression in UCEC, BLCA, COAD, KICH and BRCA and higher tumor expression in HNSC. The UCEC box plot shows higher RTL3 RNA expression in normal versus tumor tissue (log2 FC = −0.836, t-test p < 0.001).
This table shows molecular features associated with RTL3 in patient tissues and cancer cell lines. In patient samples, RTL3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RTL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
